摘要
目的 观察厄贝沙坦联合安体舒通治疗慢性心力衰竭的临床疗效并探讨其机制。方法 将142例心力衰竭患者随机分为2组，治疗组（72例）于常规治疗基础上采用厄贝沙坦联合安体舒通治疗，对照组（71例）仅行常规治疗，治疗前后作连续24hHoher监测测量及彩色多谱勒超声心动图检查。结果 治疗组较对照组能显著提高心力衰竭患者的24h心率变异性，恢复昼夜节律性（P〈0．05），治疗组与对照组LVEDV、LVESV、EF％、SBP、DBP均较治疗前改善（P〈0．05），且治疗组各项指标较对照组改善更明显（P〈0．05）。结论 厄贝沙坦与安体舒通联合使用临床效果显著和安全性良好，其机制可能是由两种药物对整个RAS可产生完全的抑制作用的结果。
Objective To observe the clinical effect and mechanism of Irbesartan together with antisterone for chronic heart failure （CHF）. Methods Altogether 143 patients with chronic heart failure of different degrees were enrolled and randomly divided into 2 groups：a treatment group with irhesartan together with antisterone treatment in 72 patients and a control group with conventional treatment in 71 patients. Hoher ECG and M - Mode Color Doppler Echocardiogram were measured before and after the treatment. Results The treatment group significantly increased the 24 - hour HRV and recovered daily rhythmicity compared with the conventional treatment （ P 〈 0. 05 ）. LVEDV ,LVESV and EF% were improved significantly in two groups （ P 〈 0. 05 ）, and the treatment group show better result （ P 〈 0. 05 ）. Conclusion Irhesartan together with antisterone are effective and safe for the treatment of chronic heart failure.
